Compounds > isoluminol
Page last updated: 2024-09-24

isoluminol

Description

isoluminol: chemiluminescent label [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID95014
CHEMBL ID14882
SCHEMBL ID28009
MeSH IDM0101393

Synonyms (40)

Synonym
nsc-13567
3682-14-2
nsc13567
mls002638327 ,
6-aminophthalazine-1,4-diol
4-aminophthalhydrazide
isoluminol
1ENU
DB02041
6-amino-2,3-dihydro-1,4-phthalazinedione
4-aminophthaloylhydrazine
smr001547813
bdbm50125767
6-amino-2,3-dihydro-phthalazine-1,4-dione
CHEMBL14882 ,
6-amino-2,3-dihydrophthalazine-1,4-dione
AE-562/42999240
HMS3086N23
A823382
nsc 13567
5id1912ana ,
1,4-phthalazinedione, 6-amino-2,3-dihydro-
unii-5id1912ana
iso-luminol
FT-0617600
AKOS015916424
TD8096
SCHEMBL28009
6-amino-phthalazine-1,4-diol
6-amino-2,3-dihydro-1,4-phthalazinedione #
AKOS024374898
AC-33250
mfcd00010560
Q27093128
AS-19110
DTXSID70958029
7-amino-4-hydroxyphthalazin-1(2h)-one
CS-W017373
HY-W016657
SY057321

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TRNA-GUANINE TRANSGLYCOSYLASEZymomonas mobilisKi8.30008.30008.30008.3000AID977610
Chain A, QUEUINE TRNA-RIBOSYLTRANSFERASEZymomonas mobilisKi8.30008.30008.30008.3000AID977610
Queuine tRNA-ribosyltransferaseZymomonas mobilis subsp. mobilis ZM4 = ATCC 31821Ki8.30000.60004.45008.3000AID228037
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID228037Inhibitory activity against eubacterial tRNA guanine transglycosylase (TGT) from Zymomonas mobilis2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Virtual screening for submicromolar leads of tRNA-guanine transglycosylase based on a new unexpected binding mode detected by crystal structure analysis.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1811Experimentally measured binding affinity data derived from PDB2001Journal of molecular biology, Feb-23, Volume: 306, Issue:3
A new target for shigellosis: rational design and crystallographic studies of inhibitors of tRNA-guanine transglycosylase.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2001Journal of molecular biology, Feb-23, Volume: 306, Issue:3
A new target for shigellosis: rational design and crystallographic studies of inhibitors of tRNA-guanine transglycosylase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (62)

TimeframeStudies, This Drug (%)All Drugs %
pre-199022 (35.48)18.7374
1990's8 (12.90)18.2507
2000's17 (27.42)29.6817
2010's13 (20.97)24.3611
2020's2 (3.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other72 (97.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
luminol[no description available]medium660
2-amino-4-hydroxypteridine[no description available]medium102-amino-4-hydroxypteridine;
pterin
2-toluidine[no description available]medium10aminotoluenecarcinogenic agent
aniline[no description available]medium10anilines;
primary arylamine
9-(4'-aminophenyl)-9h-pyrido(3,4-b)indole[no description available]medium10
pyrroles[no description available]medium10pyrrole;
secondary amine
guanine[no description available]medium102-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
queuine[no description available]medium10pyrrolopyrimidineEscherichia coli metabolite
pyrimidinones[no description available]medium10
gold[no description available]medium20copper group element atom;
elemental gold
2,2'-dipyridyl[no description available]medium10bipyridinechelator;
ferroptosis inhibitor
tripropylamine[no description available]medium10tertiary amine
tris(2,2'-bipyridine)ruthenium(II)[no description available]medium10ruthenium coordination entityfluorochrome
pheniramine[no description available]medium10pyridines;
tertiary amino compound
loratadine[no description available]medium20benzocycloheptapyridine;
ethyl ester;
N-acylpiperidine;
organochlorine compound;
tertiary carboxamide		anti-allergic agent;
cholinergic antagonist;
geroprotector;
H1-receptor antagonist
chlorpheniramine[no description available]medium10monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor
brompheniramine[no description available]medium20organobromine compound;
pyridines		anti-allergic agent;
H1-receptor antagonist
dithiadene[no description available]medium20dithiadene
cobalt[no description available]medium10cobalt group element atom;
metal allergen		micronutrient
cotinine[no description available]medium10N-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid		antidepressant;
biomarker;
human xenobiotic metabolite;
plant metabolite
nicotine[no description available]medium103-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
glucose, (beta-d)-isomer[no description available]medium30D-glucopyranoseepitope;
mouse metabolite
histamine[no description available]medium10aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
tetradecanoylphorbol acetate[no description available]medium50acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
firefly luciferin[no description available]medium301,3-thiazolemonocarboxylic acid;
benzothiazoles;
imidothioate		luciferin
acridines[no description available]medium50acridines;
mancude organic heterotricyclic parent;
polycyclic heteroarene		genotoxin
n-formylmethionine leucyl-phenylalanine[no description available]medium30tripeptide
10,10'-dimethyl-9,9'-biacridinium[no description available]medium50
sapropterin[no description available]medium105,6,7,8-tetrahydrobiopterincoenzyme;
cofactor;
diagnostic agent;
human metabolite
1-methoxy-5-methylphenazinium methyl sulfate[no description available]medium10
methylphenazonium methosulfate[no description available]medium10azaheterocycle sulfate salt;
phenazines
dehydroepiandrosterone sulfate[no description available]medium1017-oxo steroid;
steroid sulfate		EC 2.7.1.33 (pantothenate kinase) inhibitor;
human metabolite;
mouse metabolite
dehydroepiandrosterone[no description available]medium1017-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
androstanoid		androgen;
human metabolite;
mouse metabolite
17-alpha-hydroxyprogesterone[no description available]medium1017alpha-hydroxy-C21-steroid;
17alpha-hydroxy steroid;
tertiary alpha-hydroxy ketone		human metabolite;
metabolite;
mouse metabolite;
progestin
fluorescein[no description available]medium102-benzofurans;
gamma-lactone;
organic heteropentacyclic compound;
oxaspiro compound;
polyphenol;
xanthene dye		fluorescent dye;
radioopaque medium
nad[no description available]medium10organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
erythrosine[no description available]medium10
oxalic acid[no description available]medium10alpha,omega-dicarboxylic acidalgal metabolite;
human metabolite;
plant metabolite
oxalates[no description available]medium10
thyroxine[no description available]medium102-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine		antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone
3,3',5,5'-tetramethylbenzidine[no description available]medium10
progesterone 11-hemisuccinate, (11alpha)-isomer[no description available]medium2020-oxo steroid;
3-oxo-Delta(4) steroid;
dicarboxylic acid monoester;
hemisuccinate;
steroid ester
sodium azide[no description available]medium10inorganic sodium saltantibacterial agent;
explosive;
mitochondrial respiratory-chain inhibitor;
mutagen
azides[no description available]medium10pseudohalide anionmitochondrial respiratory-chain inhibitor
mocetinostat[no description available]medium10aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
4-iodophenylboronic acid[no description available]medium10
4-bromophenylboric acid[no description available]medium10
4-iodophenol[no description available]medium10iodophenol
transferrin[no description available]medium10
carnosine[no description available]medium10amino acid zwitterion;
dipeptide		anticonvulsant;
antineoplastic agent;
antioxidant;
Daphnia magna metabolite;
geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent
singlet oxygen[no description available]medium20chalcogen;
monoatomic oxygen;
nonmetal atom		macronutrient
sulfamic acid[no description available]medium10sulfamic acids
hydroxyl radical[no description available]medium10oxygen hydride;
oxygen radical;
reactive oxygen species
hydrogen carbonate[no description available]medium10carbon oxoanioncofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
n-(6-aminohexyl)-n-ethylisoluminol[no description available]medium10
chloroform[no description available]medium10chloromethanes;
one-carbon compound		carcinogenic agent;
central nervous system drug;
inhalation anaesthetic;
non-polar solvent;
refrigerant
octane[no description available]medium10alkanexenobiotic
cetyltrimethylammonium ion[no description available]medium10quaternary ammonium ion
5-bromo-4-chloro-3-indoxyl phosphate[no description available]medium10aryl phosphate;
indoles;
organobromine compound;
organochlorine compound		chromogenic compound
5-bromo-4-chloro-3-indolyl beta-galactoside[no description available]medium10beta-D-galactoside;
D-aldohexose derivative;
indolyl carbohydrate;
organobromine compound;
organochlorine compound		chromogenic compound
estriol[no description available]medium2016alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid		estrogen;
human metabolite;
human xenobiotic metabolite;
mouse metabolite
zeranol[no description available]medium20macrolide
medroxyprogesterone[no description available]medium1017alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		contraceptive drug;
progestin;
synthetic oral contraceptive
biotin[no description available]medium10biotins;
vitamin B7		coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite
zearalenone[no description available]medium10macrolide;
resorcinols		fungal metabolite;
mycoestrogen
hydrazine[no description available]medium10azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
ubiquinol[no description available]medium10polyprenylhydroquinone;
ubiquinol		biomarker;
metabolite
ubiquinone[no description available]medium10
deoxycytidine[no description available]medium10pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Bladder Cancer0low10
Bladder Neoplasms0low10
Bladder Tumors0low10
Brain Diseases0low10
Brain Disorders0low10
Brain Ischemia0low10
Cancer of Bladder0low10
Cancer of Ovary0low10
Cancer of the Bladder0low10
Cancer of the Ovary0low10
Carcinoma, Transitional Cell0low10
Central Nervous System Disorders, Intracranial0low10
Central Nervous System Intracranial Disorders0low10
Cerebral Infarction, Middle Cerebral Artery0low10
Cerebral Ischemia0low10
Chronic Disease0low10
Chronic Illness0low10
Chronically Ill0low10
CNS Disorders, Intracranial0low10
Dysentery, Bacillary0low10
Dysentery, Shiga bacillus0low10
Dysentery, Shigella boydii0low10
Dysentery, Shigella dysenteriae0low10
Dysentery, Shigella dysenteriae type 10low10
Dysentery, Shigella flexneri0low10
Dysentery, Shigella sonnei0low10
Embolic Infarction, Middle Cerebral Artery0low10
Embolus, Middle Cerebral Artery0low10
Encephalon Diseases0low10
Encephalopathy0low10
Encephalopathy, Ischemic0low10
Infarction, Middle Cerebral Artery0low10
Inflammation0low10
Innate Inflammatory Response0low10
Intracranial Central Nervous System Disorders0low10
Intracranial CNS Disorders0low10
Invasiveness, Neoplasm0low10
Ischemia, Cerebral0low10
Ischemic Encephalopathy0low10
Left Middle Cerebral Artery Infarction0low10
Liver Diseases0low10
Liver Dysfunction0low10
Malignant Tumor of Urinary Bladder0low10
MCA Infarct0low10
MCA Infarction0low10
Middle Cerebral Artery Circulation Infarction0low10
Middle Cerebral Artery Embolic Infarction0low10
Middle Cerebral Artery Embolus0low10
Middle Cerebral Artery Infarction0low10
Middle Cerebral Artery Occlusion0low10
Middle Cerebral Artery Stroke0low10
Middle Cerebral Artery Syndrome0low10
Middle Cerebral Artery Thrombosis0low10
Middle Cerebral Artery Thrombotic Infarction0low10
Neoplasm Invasion0low10
Neoplasm Invasiveness0low10
Neoplasms, Bladder0low10
Neoplasms, Ovarian0low10
Occlusion, Middle Cerebral Artery0low10
Ovarian Cancer0low10
Ovarian Neoplasms0low10
Ovary Cancer0low10
Ovary Neoplasms0low10
Pericementitis0low10
Periodontitis0low10
Pregnancy0low10
Right Middle Cerebral Artery Infarction0low10
Sensitivity and Specificity0low50
Shigella Dysentery0low10
Shigella Infection0low10
Shigellosis0low10
Stroke, Middle Cerebral Artery0low10
Thrombosis, Middle Cerebral Artery0low10
Thrombotic Infarction, Middle Cerebral Artery0low10
Urinary Bladder Cancer0low10
Urinary Bladder Neoplasms0low10

Research Highlights

Bioavailability (1)

ArticleYear
Metabolism and disposition of luminol in the rat.
Xenobiotica; the fate of foreign compounds in biological systems, Volume: 30, Issue: 3		2000
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (1)

ArticleYear
Metabolism and disposition of luminol in the rat.
Xenobiotica; the fate of foreign compounds in biological systems, Volume: 30, Issue: 3		2000
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]